Page 34 - Read Online

features and survival of hepatocellular carcinoma in Italy: impact of growth factor-like domain 7 in metastasis of human hepatocellular
stage of disease. Eur J Cancer 2001;37:239-45. carcinoma. Hepatology 2009;50:1839-50.
21. Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal 29. Iagoda AB, Koroĭ PV, Geĭvandova NI, Nikitina OA, Kastornaia IV.
growth factor, its receptor and transforming growth factor-β1 in the Growth factors and the hystologic picture of the liver in chronic viral
diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol hepatitis and hepatic cirrhosis. Klin Med (Mosk) 2006;84:44-7. (article
2013;30:673. in Russian)
22. Klocke R, Gómez-Lechón MJ, Ehrhardt A, Mendoza-Figueroa T, 30. Zhong JH, You XM, Gong WF, Ma L, Zhang Y, Mo QG, Wu LC, Xiao
Donato MT, López-Revilla R, Castell JV, Paul D. Establishment J, Li LQ. Epidermal growth factor gene polymorphism and risk of
and characterization of immortal hepatocytes derived from various hepatocellular carcinoma: a meta-analysis. PLoS One 2012;7:e32159.
transgenic mouse lines. Biochem Biophys Res Commun 2002;294:864- 31. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung
71. RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M,
23. Inoue K, Torimura T, Nakamura T, Iwamoto H, Masuda H, Abe M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene
Hashimoto O, Koga H, Ueno T, Yano H, Sata M. Vandetanib, an functional polymorphism and the risk of hepatocellular carcinoma in
inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor patients with cirrhosis. JAMA 2008;299:53-60.
development and improves prognosis of liver cancer in mice. Clin 32. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G,
Cancer Res 2012;18:3924-33. Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of
24. Yoneda N, Sato Y, Kitao A, Ikeda H, Sawada-Kitamura S, Miyakoshi Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J
M, Harada K, Sasaki M, Matsui O, Nakanuma Y. Epidermal growth Clin Oncol 2005;23:6657-63.
factor induces cytokeratin 19 expression accompanied by increased 33. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L,
growth abilities in human hepatocellular carcinoma. Lab Invest Dai Z, Papp A, Campbell A, Culler K, Balint C, O’Neil B, Lee RM,
2011;91:262-72. Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero
25. DeCicco LA, Kong J, Ringer DP. Carcinogen-induced alteration in liver M. A multi-institutional phase II study of the efficacy and tolerability
epidermal growth factor receptor distribution during the promotion of lapatinib in patients with advanced hepatocellular carcinomas. Clin
stage of hepatocarcinogenesis in rat. Cancer Lett 1997;111:149-56. Cancer Res 2009;15:5895-901.
26. Sung TI, Wang YJ, Chen CY, Hung TL, Guo HR. Increased serum 34. Sogawa C, Tsuji AB, Yoshida C, Inubushi M, Furukawa T, Koizumi M,
level of epidermal growth factor receptor in liver cancer patients and its Akahori Y, Ukai Y, Kurosawa G, Kurosawa Y, Saga T. Novel human
association with exposure to arsenic. Sci Total Environ 2012;424:74-8. monoclonal antibody against epidermal growth factor receptor as
27. Wu BW, Wu Y, Wang JL, Lin JS, Yuan SY, Li A, Cui WR. Study on an imaging probe for hepatocellular carcinoma. Nucl Med Commun
the mechanism of epidermal growth factor-induced proliferation of 2012;33:719-25.
hepatoma cells. World J Gastroenterol 2003;9:271-5. 35. Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway,
28. Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C. Novel role for epidermal therapies, and pipeline. Clin Ther 2013;35:1282-303.

Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016 25